PMID- 36267758
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221022
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 18
DP  - 2022 Sep
TI  - Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and 
      association with histologic subtypes: a multicenter retrospective study.
PG  - 961
LID - 10.21037/atm-22-3250 [doi]
LID - 961
AB  - BACKGROUND: Antiangiogenic therapy is a potential strategy against advanced 
      refractory soft tissue sarcoma (STS). This retrospective study aimed to assess 
      the efficacy and safety of apatinib in patients with advanced refractory STS and 
      explore its clinical effect on the different histologic subtypes. METHODS: 
      Patients with pathologically diagnosed and metastatic STS who had failed at least 
      standard chemotherapy and were naive to angiogenesis inhibitors were enrolled in 
      this multicenter respective study. Apatinib was administered orally at a dosage 
      of 250 to 850 mg/day. The primary endpoints were objective response rate (ORR) 
      and disease control rate (DCR). The secondary endpoints were progression free 
      survival (PFS) and overall survival (OS). Tumor assessment was done after the 
      first 4 weeks and every 8 weeks thereafter. RESULTS: Twenty-six patients were 
      enrolled from seven centers between December 2015 and December 2020, consisting 
      of 9 leiomyosarcomas (LMS), 4 rhabdomyosarcomas (RMS), 3 undifferentiated 
      pleomorphic cell sarcomas (UPS), 3 fibrosarcomas (FS), 3 alveolar soft part 
      sarcomas (ASPS), 2 angiosarcomas (AS) and 2 synovial sarcomas (SS). The median 
      age was 49.0 [26-77] years, 15 females and 11 males. The ORR was 34.62% [9/26, 
      95% confidence interval (CI): 19.42-53.78%] and DCR was as high as 84.62% (22/26, 
      95% CI: 66.47-93.85%). The median progression-free survival and overall survival 
      were 6.0 months (95% CI: 2.42-9.58) and 19.3 months (95% CI: 7.31-31.29) 
      respectively. Furthermore, 181 patients from seven studies as well as this trial 
      were included for pooled analysis of apatinib efficacy dependency on histology. 
      In terms of ORR, RMS (41.7%), ASPS (78.6%), and Ewing sarcoma (40.7%) seemed to 
      benefit more than the other histologic subtypes. Common adverse events (AEs) 
      included hand-foot skin reaction (n=13, 50.0%), hypertension (n=12, 46.15%), 
      proteinuria (n=10, 38.46%). Seven patients (7/26, 26.92%) had grade 3 AEs and no 
      grade 4 AEs occurred. 2 patients (2/26, 7.69%) and 15 patients (15/26, 57.69%) 
      experienced dose withdrawal and dose reduction respectively. CONCLUSIONS: 
      Apatinib showed promising efficacy and a manageable safety profile in patients 
      with advanced refractory STS. In addition, the response to apatinib in STS seemed 
      to be dependent on histology.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Wang, Xiangling
AU  - Wang X
AD  - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, 
      China.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, 
      China.
FAU - Sun, Baoyong
AU  - Sun B
AD  - Fifteenth Inpatient Area of Surgery, Shandong Cancer Hospital Affiliated to 
      Shandong University, Jinan, China.
FAU - Sun, Yuping
AU  - Sun Y
AD  - Department of Proton Center, Shandong Cancer Hospital Affiliated to Shandong 
      University, Jinan, China.
FAU - Liu, Ning
AU  - Liu N
AD  - Department of Oncology, Jining First People's Hospital, Jining, China.
FAU - Niu, Xuecai
AU  - Niu X
AD  - Department of Radiation Therapy, The Forth People's Hospital of Jinan, Jinan, 
      China.
FAU - Li, Chunhua
AU  - Li C
AD  - Second Affiliated Hospital of Shandong University of Traditional Chinese 
      Medicine, Jinan, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, 
      China.
FAU - Zhang, Qiang
AU  - Zhang Q
AD  - Department of Oncology, The Fourth People Hospital of Zibo, Zibo, China.
FAU - Hao, Jing
AU  - Hao J
AD  - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, 
      China.
FAU - Wang, Xiuwen
AU  - Wang X
AD  - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, 
      China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9577742
OTO - NOTNLM
OT  - Apatinib
OT  - advanced refractory soft tissue sarcoma
OT  - efficacy
OT  - safety
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-3250/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/10/22 06:00
MHDA- 2022/10/22 06:01
PMCR- 2022/09/01
CRDT- 2022/10/21 03:00
PHST- 2022/05/20 00:00 [received]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/10/21 03:00 [entrez]
PHST- 2022/10/22 06:00 [pubmed]
PHST- 2022/10/22 06:01 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - atm-10-18-961 [pii]
AID - 10.21037/atm-22-3250 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Sep;10(18):961. doi: 10.21037/atm-22-3250.